Ductal carcinoma in situ arising within a benign phyllodes tumour is a rare neoplasm of the breast. We present a case of a 19-year-old woman who had a right breast lump for six months with the above diagnosis together with a mini-review of the literature. Ultrasound revealed a 5-cm breast lump and core biopsy revealed ductal carcinoma in situ. She underwent wide local excision of the breast lump with clear margins. Final histology confirmed ductal carcinoma in situ within a fibroepithelial lesion consistent with a benign phyllodes tumour. To our knowledge, this is the youngest case of ductal carcinoma in situ arising in a phyllodes tumour to have been reported so far.

Phyllodes tumours are fibroepithelial breast tumours; they account for less than 1% of all breast neoplasms.1 Phyllodes tumours have characteristic epithelial components arranged in clefts, surrounded by a mesenchymal component organised in a leaflike pattern.2 Although malignant transformation of the stromal component can occur, a carcinoma arising from the epithelial component is only rarely reported. To date, 41 cases of breast cancer arising from phyllodes tumours have been reported, of which 19 were reported to be ductal carcinoma in situ (DCIS). We present a review and a case discussion of a 19-year-old woman diagnosed with DCIS arising from a phyllodes tumours, the youngest case to date, who was successfully managed with oncoplastic breast conserving surgery.

A 19-year-old single nulliparous woman presented with six months’ history of a rapidly enlarging right breast lump. Family history was significant for an aunt with breast cancer at the age of 60 years. On clinical examination, the mass measured 5 cm and was firm, non-tender, mobile and well defined in the upper outer quadrant of the right breast. There were no skin or nipple changes. Examination of the left breast was normal. There were no palpable axillary lymph nodes. Ultrasonography of the right breast revealed a heterogeneous vascular mass with fairly well circumscribed margins in the right breast at 9–10 o'clock 5 cm from nipple, measuring 5 x 2.8 x 5.1 cm (Fig 1). An ultrasound-guided biopsy was performed in view of clinical suspicion and histology showed a low to intermediate grade DCIS. Bilateral mammograms subsequently performed showed a mass with partially obscured borders in the right upper outer quadrant, with a couple of scattered specks of benign coarse calcifications in right breast (Fig 2). There were no other suspicious lesions in either breast. Considering the patient’s age, size of lesion and histology, she was counselled for mastectomy with implant reconstruction. She declined mastectomy and subsequently underwent a wide local excision and sentinel lymph node biopsy via an inframammary fold incision. The usual practice in our centre is to excise breast tissue down to the pectoral fascia. Intraoperative frozen section of two sentinel axillary lymph nodes was negative for malignancy. Parenchymal flaps were mobilised to close the defect. Histopathological examination showed a well-circumscribed fibroepithelial lesion consistent with a benign phyllodes tumours with diffuse involvement of the ductal epithelial component by multiple foci of low to intermediate nuclear grade DCIS (Figs 3 and 4). The fibroepithelial lesion showed focal leaf-like architectural pattern. The epithelial component also displayed features of columnar cell change and usual type ductal hyperplasia. There was no definite evidence of invasive carcinoma. All resection margins were free of malignancy with nearest 0.1 cm from posterior margin. After discussion with the radiation oncologist, in view of the substantial risk considering her age, it was decided to omit adjuvant radiotherapy, accepting that there will be higher risks of local recurrence. She was subsequently started on chemoprevention with tamoxifen. Surveillance ultrasound performed this February revealed no recurrence or new lesions. All genetic screening for hereditary breast cancer syndromes including BRCA1, BRCA2 and PTEN were negative.

figure parent remove

Figure 1 Ultrasound scan of the right breast revealing a heterogeneous vascular mass with fairly well-circumscribed margins in the right breast

figure parent remove

Figure 2 Bilateral mammography showing a mass with partially obscured borders in the right upper outer quadrant with couple of scattered specks of benign coarse calcifications in right breast

figure parent remove

Figure 3 Fibroepithelial tumour with focal leaf-like architecture. There is secondary involvement of the ductal epithelial component by foci of ductal carcinoma in-situ (40 x magnification)

figure parent remove

Figure 4 Secondary involvement of the ductal epithelial component of the fibroepithelial tumour by foci of ductal carcinoma in-situ (40 x magnification)

Phyllodes tumours are graded according to their stromal characteristics, namely benign, borderline or malignant,3 with recurrences occurring at a rate of 17%, 25% and 27%, respectively.4 The classification is based on histological characteristics of the phyllodes tumours and is used to prognosticate their clinical course. Most series-reported benign phyllodes represented 50–70% of phyllodes tumours.1,3 DCIS or invasive breast carcinomas can occur in conjunction with phyllodes tumours, but are very uncommon, occurring in only about 1% of patients with phyllodes tumours.5

A literature search of PubMed was conducted using the keywords: ‘breast cancer’, ‘phyllodes tumor’, ‘carcinoma in situ’, ‘cystosarcoma phyllodes’ and ‘DCIS’. Only 41 cases of carcinoma arising in patients with phyllodes tumours (Table 1) were identified, of which 19 were DCIS.540

Table

Table 1 Published data on carcinomas arising within phyllodes tumours.

Table 1 Published data on carcinomas arising within phyllodes tumours.

Authors Year Age (years) Surgery Phyllodes grade Size Epithelial type Size Axillary lymph node involvement
Norris et al. 1967 Invasive carcinoma (two cases)
Cornog et al. 1971 Squamous cell carcinoma
Pietruska et al. 1978 45 5.5 Invasive carcinoma Negative
Seemayer et al. 1975 27 Mastectomy Malignant 6.0 Ductal carcinoma in situ Focal
Bassermann et al. 1980 Squamous cell carcinoma
Leong et al. 1980 49 Local excision Benign 6 Lobular carcinoma in situ
Leong et al. 1980 51 Mastectomy Benign 4 Invasive ductal carcinoma Negative
Klausner et al. 1983 60 Mastectomy Malignant 4 Invasive ductal carcinoma Negative
Cole-Beuglet et al. 1983 60 Local excision Benign 3 Invasive ductal carcinoma Focal Negative
Cole-Beuglet et al. 1983 55 Local excision Benign 3.5 Ductal carcinoma in situ + lobular carcinoma in situ
Hunger et al. 1984 57 Mastectomy Malignant 15.5 Squamous cell carcinoma
Ishida et al. 1984 41 Mastectomy Benign 5.6 Invasive ductal carcinoma Focal Negative
Grove et al. 1986 71 Mastectomy Benign 19.0 Ductal carcinoma in situ 2 Negative
Ward et al. 1986 55 Mastectomy Benign 4.0 Lobular carcinoma in situ Focal
Knudsen et al. 1987 71 Mastectomy Benign 7.0 Ductal carcinoma in situ + lobular carcinoma in situ Multi-focal Negative
Yasumura et al. 1988 47 Mastectomy Benign 13.0 Invasive ductal carcinoma Focal Negative
De Rosa et al. 1989 77 Mastectomy Benign 5.0 Ductal carcinoma in situ 0.3 Negative
Schwickerath et al. 1992 47 Mastectomy Malignant 2.0 Ductal carcinoma in situ Negative
Padmanabhan et al. 1997 47 Mastectomy Malignant 7.5 Lobular carcinoma in situ Focal Negative
Naresh 1997 51 Local excision Borderline 14.0 Ductal carcinoma in situ Focal
Nishimura et al. 1998 80 Local excision Malignant 10.5 Ductal carcinoma in situ
Alo et al.. 2001 39 Mastectomy Malignant 9.0 Ductal carcinoma in situ
Kodama et al. 2003 47 Mastectomy Benign 17.0 Invasive lobular carcinoma Focal Negative
Parfitt et al. 2004 26 Local excision Benign 3.3 Ductal carcinoma in situ and invasive carcinoma (no special type) Positive (4/13)
Lim et al. 2005 45 Mastectomy Malignant 12.0 Ductal carcinoma in situ 0.6
Tokudome et al. 2005 59 Mastectomy 3.5 Invasive carcinoma Negative
Ramdass et al. 2006 69 Benign Squamous cell carcinoma
Nomura et al. 2006 75 Mastectomy Malignant 3.5 Ductal carcinoma in situ
Sugie et al. 2007 54 Mastectomy Malignant 8.0 Squamous cell carcinoma Negative
Korula et al. 2008 51 Mastectomy Malignant 21.0 Ductal carcinoma in situ and invasive ductal carcinoma Positive (2/12)
Yamaguchi et al. 2008 54 Mastectomy Benign 15.0 Ductal carcinoma in situ Focal
Macher-Goeppinger et al. 2010 70 Mastectomy Malignant 6.0 Invasive ductal carcinoma 2.5 Negative
Kuo et al. 2010 24 Mastectomy Borderline Ductal carcinoma in situ and invasive ductal carcinoma Positive (1/2)
Nio et al. 2010 53 Local excision Benign 3.5 Ductal carcinoma in situ 0.5
Yoshinori Nio et al. 2011 53 Local excision Benign 3.5 Ductal carcinoma in situ Focal
Gina Shirah et al. 2011 49 Local excision Benign 5.0 Lobular carcinoma in situ and invasive lobular carcinoma 0.2
Prithwijit Ghosh et al. 2015 42 Local excision Benign 2.2 Ductal carcinoma in situ
Sharat et al. 2015 23 Local excision Benign 5.0 Ductal carcinoma in situ Focal
Nancy et al. 2017 70 Local excision Beenign 2.3 Ductal carcinoma in situ and invasive ductal carcinoma 0.5 Negative

Of the 19 cases with DCIS, all were female, with ages ranging from 23 to 80 years. To our knowledge, our case is the youngest patient to have been diagnosed with DCIS within a phyllodes tumour. Four cases had concomitant invasive components,26,32,35 while two other cases had concomitant LCIS.12,17 Six arose from malignant phyllodes tumours, two from borderline phyllodes tumours and ten from benign phyllodes tumours. However, among the ten cases, only six had pure DCIS from benign phyllodes tumours, ours being the seventh case to be reported in the English literature.5,15,19,33,36,39

The size of the phyllodes tumours ranged widely between 2.0 cm and 21.0 cm, suggesting that DCIS can occur in any palpable phyllodes tumour. Eight cases underwent wide local excision while the rest underwent total mastectomy.

Apart from four cases of DCIS with invasive components, the remainder of the patients with DCIS had negative lymph node involvement or did not undergo axillary lymph nodal sampling or dissection. Three cases reported with positive axillary lymph node involvement had invasive carcinomas.

Stromal overgrowth has been reported with rapidly enlarging phyllodes tumours; epithelial hyperplasia has also been reported to occur in as high as 74% of phyllodes tumours.41 The best-practice diagnostic guidelines published by the Cancer Reform Strategy Breast Cancer Working Group does not recommend biopsy in women younger than 25 years of age with ultrasound showing typical features of fibroadenoma.42 In this patient, however, the clinically rapidly enlarging size and heterogenicity of the lesion on ultrasound were suspicious, hence a biopsy was performed.

Standard treatment for phyllodes tumours involves surgical resection with no need for axillary sampling or dissection. However, adjuvant therapy may be indicated for patients with epithelial malignant change, be it radiotherapy, chemotherapy or endocrine therapy. Patients with DCIS who have had breast-conserving surgery are typically offered adjuvant radiotherapy to reduce local recurrence rates. Young age at diagnosis has been reported to be an independent predictor for local recurrence even after controlling for factors such as tumour size, presence of comedonecrosis and clinical presentation.43,44

A local study by Tan et al. showed a local recurrence rate of 10.9% for benign phyllodes tumours with no distant metastases.45 From this study, the predicted recurrence-free survival from the normogram is more than 0.95 at 10 years for our patient. According to another validated normogram published in the Journal of Clinical Oncology in 2010 for the Western population, the ipsilateral breast tumour recurrence rate is about 0.2 at 10 years.46 Based on the University of South California/Van Nuys Prognostic Index, our patient had intermediate-risk DCIS. A 2008 study by Di Saverio showed a 10-year disease-free survival of 86.8% for patients who underwent radiotherapy and 78.5% for those who did not, although this was not significant.47 Interestingly, a more recent study by Kim et al. showed that patients with intermediate risk DCIS who did not undergo radiotherapy had no recurrence.48 Fortunately, a 2015 analysis assessing 20-year mortality outcomes in patients with DCIS demonstrated no survival benefit to radiation, although it did reduce local recurrence risks significantly.49 Radiation-related risks of thyroid, breast, brain, skin cancers, as well as leukaemia in children have been demonstrated in a linear dose–response relationship, with risks of cancer greatest for those exposed early in life, and these risks appear to persist throughout life.50 In the Childhood Cancer Survivor Study group, the odds ratio for breast cancer increased linearly with radiation dose, with 11-fold increase for local breast doses of approximately 40 Gy relative to no radiation.51 A dose–response relationship was also observed by Rubino, who showed that risk of post-radiation sarcoma in breast cancer patients was 30.6 times higher for doses of more than 44 Gy compared with those of less than 15 Gy.52 However, boost radiation has also been reported by the Rare Cancer Network study to decrease local recurrence rates, particularly in young women less than 45 years of age with DCIS, with 10-year local relapse-free survival of 86% with boost radiation and 72% without.53 In our case, the patient received chemoprevention with tamoxifen and is still on regular follow-up.

In conclusion, we present a rare case of DCIS arising within benign phyllodes tumor, which is the youngest reported to date. Adjuvant therapy needs to be further investigated and this group of patients should be followed up long-term given their higher rates of local recurrence.

1. Tan PH, T.G., Lee A, Simpson JF, Hanby AM, Fibroepithelial Tumours. In: Lakhani SR, Ellis IO, Schnitt SJ et al., WHO Classification of Tumours of the Breast. 4th ed. Geneva: WHO; 2012. pp. 142147. Google Scholar
2. Moinfar F. Biphasic tumors. In: Essentials of Diagnostic Breast Pathology: A Practical Approach, Heidelberg: Springer; 2007. pp. 320350. Google Scholar
3. Rosen PP. Rosen's Breast Pathology. 2nd ed. Philadelphia, PA: Lippincott-Raven, 2001. p. 325364. Google Scholar
4. Tavassoli FA. Tumours of the Breast and Female Genital Organs. Pathology and genetics of tumours of the digestive system. World Health Organization Classification of Tumours. Lyon: IARC Press; 2003. pp. 99103. Google Scholar
5. Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20(12): 2,0902,099. CrossrefGoogle Scholar
6. Cornog JL, Mobini J, Steiger E, Enterline HT. Squamous carcinoma of the breast. Am J Clin Pathol 1971; 55(4): 410417. Crossref, MedlineGoogle Scholar
7. Pietruszka M, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 1978; 41(5): 1,9741,983. CrossrefGoogle Scholar
8. Seemayer TA, Tremblay G, Shibata H. The unique association of mammary stromal sarcoma with intraductal carcinoma. Cancer 1975; 36(2): 599605. Crossref, MedlineGoogle Scholar
9. Bassermann R, Eiermann W. [Cystosarcoma phylloides of the breast and bilateral breast cancer. Case report]. Pathologe 1980; 1(3): 155158. MedlineGoogle Scholar
10. Leong AS, Meredith DJ. Tubular carcinoma developing within a recurring cystosarcoma phyllodes of the breast. Cancer 1980; 46(8): 1,8631,867. CrossrefGoogle Scholar
11. Klausner JM, Lelcuk S, Ilia B et al. Breast carcinoma originating in cystosarcoma phyllodes. Clin Oncol 1983; 9(1): 7174. MedlineGoogle Scholar
12. Cole-Beuglet C, Soriano R, Kurtz AB et al. Ultrasound, x-ray mammography, and histopathology of cystosarcoma phylloides. Radiology 1983; 146(2): 481486. Crossref, MedlineGoogle Scholar
13. Hunger E, Turk R, Wurster K. [Malignant cystosarcoma phylloides and squamous cell carcinoma of the breast. A rare tumor combination]. Geburtshilfe Frauenheilkd 1984; 44(10): 640642. Crossref, MedlineGoogle Scholar
14. Ishida T, Izuo M, Kawai T. Breast carcinoma arising in cystosarcoma phyllodes: report of a case with a review of the literature. Jpn J Clin Oncol 1984; 14(1): 99106. MedlineGoogle Scholar
15. Grove A, Deibjerg Kristensen L. Intraductal carcinoma within a phyllodes tumor of the breast: a case report. Tumori 1986; 72(2): 187190. Crossref, MedlineGoogle Scholar
16. Ward RM, Evans HL. Cystosarcoma phyllodes. A clinicopathologic study of 26 cases. Cancer 1986; 58(10): 2,2822,289. CrossrefGoogle Scholar
17. Knudsen PJ, Ostergaard J. Cystosarcoma phylloides with lobular and ductal carcinoma in situ. Arch Pathol Lab Med 1987; 111(9): 873875. MedlineGoogle Scholar
18. Yasumura T, Matsui S, Hamajima T et al. Infiltrating ductal carcinoma developing within cystosarcoma phyllodes: a case report. Jpn J Surg 1988; 18(3): 326329. Crossref, MedlineGoogle Scholar
19. de Rosa G, Ferrara G, Goglia P et al. In situ and microinvasive carcinoma with squamoid differentiation arising in a phyllodes tumor: report of a case. Tumori 1989; 75(5): 514517. Crossref, MedlineGoogle Scholar
20. Schwickerath J, Blessing MH, Wolff F. [A rare clinical manifestation of a combination tumor of cystosarcoma phylloides malignum and an intraductal cancer]. Geburtshilfe Frauenheilkd 1992; 52(9): 557559. Crossref, MedlineGoogle Scholar
21. Padmanabhan V, Dahlstrom JE, Chong GC, Bennett G. Phyllodes tumor with lobular carcinoma in situ and liposarcomatous stroma. Pathology 1997; 29(2): 224226. Crossref, MedlineGoogle Scholar
22. Deodhar K., Baraniya JB, Naresh KN et al. Cancerization of phyllodes tumour. Histopathology 1997; 30(1): 9899. Crossref, MedlineGoogle Scholar
23. Nishimura R, Hasebe T, Imoto S, Mukai K. Malignant phyllodes tumour with a noninvasive ductal carcinoma component. Virchows Arch 1998; 432(1): 8993. Crossref, MedlineGoogle Scholar
24. Alò PL, Andreano T, Monaco S et al. [Malignant phyllode tumor of the breast with features of intraductal carcinoma]. Pathologica 2001; 93(2): 124127. MedlineGoogle Scholar
25. Kodama T, Kameyama K, Mukai M et al. Invasive lobular carcinoma arising in phyllodes tumor of the breast. Virchows Arch 2003; 442(6): 614616. MedlineGoogle Scholar
26. Parfitt JR, Armstrong C, O’malley F et al. In-situ and invasive carcinoma within a phyllodes tumor associated with lymph node metastases. World J Surg Oncol 2004; 2: 46. Crossref, MedlineGoogle Scholar
27. Lim SM, Tan PH. Ductal carcinoma in situ within phyllodes tumour: a rare occurrence. Pathology 2005; 37(5): 393396. Crossref, MedlineGoogle Scholar
28. Tokudome N, Sakamoto G, Sakai T et al. A case of carcinosarcoma of the breast. Breast Cancer 2005; 12(2): 149153. Crossref, MedlineGoogle Scholar
29. Ramdass MJ, Dindyal S. Phyllodes breast tumour showing invasive squamous-cell carcinoma with invasive ductal, clear-cell, secretory, and squamous components. Lancet Oncol 2006; 7(10): 880. Crossref, MedlineGoogle Scholar
30. Nomura M, Inoue Y, Fujita S et al. A case of noninvasive ductal carcinoma arising in malignant phyllodes tumor. Breast Cancer 2006; 13(1): 8994. Crossref, MedlineGoogle Scholar
31. Sugie T, Takeuchi E, Kunishima F et al. A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer 2007; 14(3): 327332. Crossref, MedlineGoogle Scholar
32. Korula A, Varghese J, Thomas M et al. Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis. Singapore Med J 2008; 49(11): e318e321. MedlineGoogle Scholar
33. Yamaguchi R, Tanaka M, Kishimoto Y et al. Ductal carcinoma in situ arising in a benign phyllodes tumor: report of a case. Surg Today 2008; 38(1): 4245. Crossref, MedlineGoogle Scholar
34. Macher-Goeppinger S, Marme F, Goeppert B et al. Invasive ductal breast cancer within a malignant phyllodes tumor: case report and assessment of clonality. Hum Pathol 2010; 41(2): 293296. Crossref, MedlineGoogle Scholar
35. Kuo YJ, Ho DM, Tsai YF, Hsu CY. Invasive ductal carcinoma arising in phyllodes tumor with isolated tumor cells in sentinel lymph node. J Chin Med Assoc 2010; 73(11): 602604. Crossref, MedlineGoogle Scholar
36. Nio Y, Iguchi C, Tsuboi K, Maruyama R. Ductal carcinoma in situ arising within a benign phyllodes tumor: A case report with a review of the literature. Oncol Lett 2011; 2(2): 223228. Crossref, MedlineGoogle Scholar
37. Shirah GR, Lau SK, Jayaram L et al. Invasive lobular carcinoma and lobular carcinoma in situ in a phyllodes tumor. Breast J 2011; 17(3): 307309. Crossref, MedlineGoogle Scholar
38. Ghosh P, Saha K. Ductal carcinoma in situ in a benign phyllodes tumor of breast: A rare presentation. J Nat Sci Biol Med 2014; 5(2): 470472. Crossref, MedlineGoogle Scholar
39. Chopra S, Muralikrishnan V, Brotto M. Youngest case of ductal carcinoma in situ arising within a benign phyllodes tumour: A case report. Int J Surg Case Rep 2016; 24: 6769. Crossref, MedlineGoogle Scholar
40. Panko N, Jebran AA, Gomberawalla A, Connolly M. Invasive ductal carcinoma within a benign phyllodes tumor. Am J Case Rep 2017; 18: 813816. Crossref, MedlineGoogle Scholar
41. Tan PH, Jayabaskar T, Chuah KL et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 2005; 123(4): 529540. Crossref, MedlineGoogle Scholar
42. Willett AM, Michell MJ, Lee MJR, eds. Best Practice Diagnostic Guidelines for Patients Presenting with Breast Symptoms. London: Department of Health; 2010. Google Scholar
43. Kong I, Narod SA, Taylor C et al. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 2014; 21(1): e96e104. Crossref, MedlineGoogle Scholar
44. Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103(6): 478488. Crossref, MedlineGoogle Scholar
45. Tan PH, Thike AA, Tan WJ et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 2012; 65(1): 6976. Crossref, MedlineGoogle Scholar
46. Rudloff U, Jacks LM, Goldberg JI et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010; 28(23): 3,7623,769. CrossrefGoogle Scholar
47. Di Saverio, S., et al, 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008. 109(3): 40516. Crossref, MedlineGoogle Scholar
48. Kim T, Catena F, Santini D et al. Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery? Springerplus 2014; 3: 405416. Crossref, MedlineGoogle Scholar
49. Narod SA, Iqbal J, Giannakeas V et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1(7): 888896. Crossref, MedlineGoogle Scholar
50. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006; 36(Suppl 2): 121125. Crossref, MedlineGoogle Scholar
51. Inskip PD, Robison LL, Stovall M et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009; 27(24): 3,9013,907. CrossrefGoogle Scholar
52. Rubino C, Shamsaldin A, MG et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89(3): 277288. Crossref, MedlineGoogle Scholar
53. Omlin A, Amichetti M, Azria D et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006; 7(8): 652656. Crossref, MedlineGoogle Scholar

Article Metrics

Views
172
Citations
Crossref 2
About article usage data:

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar tempor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Bookmark and share